Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Libtayo Market Evolved, and What Are Its Growth Projections? .Market Growth from 2024 to 2025: oThe Libtayo ...

Libtayo was approved by the US Food and Drug Administration (FDA) as a first-line (1L) therapy for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. On World ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...

BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ended in failure.